PATENT CLAIM ANALYSIS

Application Number: 16331579
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "260100"]

Abstract:
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

Claim (Index 6):
The compound according to  claim 1 , wherein\n R 1  is CF 3 ; R 2  is hydrogen; L 1  is a 8- to 9-membered fused heterocycle of Formula (a-1) or (a-2) (a) L 2  is >CH 2 ; and R 3  is Ar; or Het 1 ; or (b) L 2  is >CH 2 ; and R 3  is \u2014Ge(CH 3 ) 3 ; wherein Ar is phenyl optionally substituted with a halo substituent; and Het 1  is a monocyclic heteroaryl selected from the group consisting of pyridyl, 4-, 5- or 6-pyrimidinyl, pyrrolyl, pyrazolyl, and 4- or 5-thiazolyl; each of which may be optionally substituted with a halo or a C 1-4 alkyl substituent.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 1.34146
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15766887', '15537619', '15976037', '15537551', '15976223']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7907382087300793
- 35 USC 102 Novelty (BERT): 0.5202266989084082
- Combined Prediction Score: 0.7636870577479121
- Mean Citation Score: 294.28313799999995
- Max Citation Score: 308.84235
- Similarity Product: 237.13006856385468

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test